Evidence map›Paper›PMID 30636831›Full record

ArticleIndian journal of pharmacology

A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.

Pramod Kumar Sharma, Arup Kumar Misra, Ajay Gupta, Surjit Singh, Puneet Dhamija, Puneet Pareek

Abstract read
In one paragraph

Article in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pramod Kumar SharmaDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Arup Kumar MisraDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Ajay GuptaDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Surjit SinghDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Puneet DhamijaDepartment of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Puneet PareekDepartment of Radiotherapy, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND

methodsData on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology. Descriptive statistic was used to summarize and analyze the available data, namely patient demography, causality, severity, and preventability of the event.

resultsA total of 191 chemotherapy-induced ADR reports were received from 164 patients during the period March 2015 to August 2017. Almost three-fourth of the ADRs occurred in patients who were receiving regimens involving multiple drugs. Taxanes, alkylating agents, and platinum compounds were the common drug groups involved. The skin (

conclusionChemotherapy-related ADRs among cancer patients are worrisome. It has a negative impact on patient quality of life and in addition increases cost of therapy. It is found that timely reporting of chemotherapy-related ADRs and having an effective ADR monitoring system in place ensure preventability of the ADRs in many cases. Oncologists, Radiotherapists and Onco-surgeons should be actively involved in ADR reporting (Onco-Pharmacovigilance) and exchange constructive information, update and educate each other about appropriate use of anticancer drugs. Onco-pharmacovigilance is the need of the hour and could be of immense value in reducing morbidity and mortality if practiced with utmost importance.

Indexed as

PharmacovigilanceQuality of LifeAdolescentAdultAdverse Drug Reaction Reporting SystemsAgedAntineoplastic AgentsChildChild, PreschoolCohort StudiesFemaleHumansIndiaInfantInfant, NewbornMaleAntineoplastic AgentsAdverse drug reactionschemotherapyonco-pharmacovigilancepreventabilityseverity

Identifiers

PMID30636831
PMCPMC6302695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.